TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity by Moudry, Pavel et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines
PARP inhibitor sensitivity
Moudry, Pavel; Watanabe, Kenji; Wolanin, Kamila M.; Bartkova, Jirina; Wassing, Isabel E.;
Watanabe, Sugiko; Strauss, Robert; Pedersen, Rune Troelsgaard; Østergaard, Vibe
Hallundbæk; Lisby, Michael; Andújar-Sánchez, Miguel; Maya-Mendoza, Apolinar; Esashi,
Fumiko; Lukas, Jiri; Bartek, Jiri
Published in:
The Journal of Cell Biology
DOI:
10.1083/jcb.201507042
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-SA
Citation for published version (APA):
Moudry, P., Watanabe, K., Wolanin, K. M., Bartkova, J., Wassing, I. E., Watanabe, S., ... Bartek, J. (2016).
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
The Journal of Cell Biology, 212(3), 281-288. https://doi.org/10.1083/jcb.201507042
Download date: 03. Feb. 2020
JCB
JCB: Report
281
The Rockefeller University Press  $30.00
J. Cell Biol. Vol. 212 No. 3 281–288
www.jcb.org/cgi/doi/10.1083/jcb.201507042
Introduction
Synthetic lethality is a genetic concept whereby a combina-
tion or synthesis of mutations in multiple genes results in cell 
death, whereas inactivation of single genes does not affect cell 
viability. This concept has been exploited in cancer treatment 
with promising clinical results. Indeed, cancer patients with 
BRCA1 or BRCA2 gene mutations benefit from treatment with 
a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi; Lord 
et al., 2015). PARP1/2i olaparib has been recently approved for 
treatment of ovarian cancer patients with BRCA1/2 defects in 
Europe and the United States.
PARP1 plays an important role in DNA repair, especially 
in repair of DNA single-strand breaks via base excision repair. 
On DNA damage, PARP1 binds DNA via its N-terminal zinc 
finger motifs, accumulates at DNA damage sites, and regulates 
accumulation of DNA repair proteins by generation of PAR 
chains (Luo and Kraus, 2012). Because of negative charge of 
PAR polymers, autoPARylation of PARP1 itself eventually 
causes its dissociation from DNA. A recent model suggests 
that olaparib and other PARPis trap PARP1 at DNA and pre-
vent its release (Murai et al., 2012), thereby creating obstacles 
for replication forks. The observation that stalled replication 
forks require functional homologous recombination (HR) for 
restart likely explains the synthetic lethality interaction between 
BRCA1/2 genes and PARPi. In addition to BRCA1 and BRCA2 
genes (Bryant et al., 2005; Farmer et al., 2005), several other 
PARPi sensitivity-causing DNA damage response (DDR) de-
fects, in several DDR kinases and repair proteins, have been 
reported (Lord et al., 2015).
Topoisomerase IIβ-binding protein 1 (TOP BP1) participates in DNA replication and DNA damage response; however, 
its role in DNA repair and relevance for human cancer remain unclear. Here, through an unbiased small interfering RNA 
screen, we identified and validated TOP BP1 as a novel determinant whose loss sensitized human cells to olaparib, an 
inhibitor of poly(ADP-ribose) polymerase. We show that TOP BP1 acts in homologous recombination (HR) repair, impacts 
olaparib response, and exhibits aberrant patterns in subsets of human ovarian carcinomas. TOP BP1 depletion abro-
gated RAD51 loading to chromatin and formation of RAD51 foci, but without affecting the upstream HR steps of DNA 
end resection and RPA loading. Furthermore, TOP BP1 BRCT domains 7/8 are essential for RAD51 foci formation. 
Mechanistically, TOP BP1 physically binds PLK1 and promotes PLK1 kinase–mediated phosphorylation of RAD51 at 
serine 14, a modification required for RAD51 recruitment to chromatin. Overall, our results provide mechanistic insights 
into TOP BP1’s role in HR, with potential clinical implications for cancer treatment.
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There are two major pathways for DNA double-strand 
breaks (DSBs) repair: nonhomologous end joining and HR, 
which, unlike nonhomologous end joining, requires sister 
chromatid and therefore is restricted to S and G2 phases of the 
cell cycle. HR starts with 5′ to 3′ resection of DNA ends that 
generates single-stranded DNA (ssDNA) ends. The ssDNA is 
rapidly coated by replication protein A (RPA), which is then 
replaced by RAD51 (Jackson and Bartek, 2009). RAD51 fil-
aments promote DNA strand invasion and ensue HR. Al-
though a BRCA1–PALB2–BRCA2 complex promotes RAD51 
loading on chromatin (Sy et al., 2009), regulation and ad-
ditional factors involved in RAD51 chromatin loading are 
incompletely understood.
Topoisomerase IIb–binding protein 1 (TOP BP1) was ini-
tially identified as a factor interacting with C-terminal region 
of DNA topoisomerase IIβ (Yamane et al., 1997). TOP BP1 is 
a large, nine BRCT domain–containing protein with essential 
roles in cellular processes, including DNA repair, replication, 
and transcription (Sokka et al., 2010). TOP BP1 enhances ATR 
kinase activity (Kumagai et al., 2006) through interaction with 
ATR partner protein ATR IP (Mordes et al., 2008). Ectopic ex-
pression of the ATR-activation domain (AAD) of TOP BP1 is 
sufficient to activate ATR in the absence of DNA damage and 
leads to cell cycle arrest (Toledo et al., 2008). TOP BP1 does 
not possess any known enzymatic activity; it rather serves as 
a scaffold protein for numerous interacting proteins that bind 
to its BRCT domains. Although TOP BP1 contributes to DNA 
repair and was suggested to be involved in HR (Morishima et 
al., 2007), any mechanistic insights into TOP BP1’s functions in 
DNA repair are missing. Here we report on a mechanism through 
which TOP BP1 regulates HR and impacts PARPi sensitivity.
Results and discussion
To identify factors that mediate sensitivity to PARPi olaparib, we 
performed a high-content RNAi screen in human osteosarcoma 
cell line U2OS (Frankum et al., 2015). Among other hits, we 
identified TOP BP1 as a candidate protein whose depletion 
enhanced the toxic effect of PARPi. These results suggested 
that loss of TOP BP1 could sensitize tumor cells to PARPi and 
that loss or inactivation of TOP BP1 could predict response to 
this class of agents. To validate the screen data we first used an 
independent siRNA to assess induction of micronuclei and DNA 
damage in TOP BP1-depleted cells exposed to olaparib for 3 
d. TOP BP1 siRNA combined with olaparib caused micronuclei 
formation and increased the level of a DNA damage marker, 
histone H2A.X phosphorylated at serine 139 (γH2AX), to an 
extent equivalent to that achieved by a siRNA targeting BRCA2 
(Fig.  1, A–C). Next, we tested olaparib sensitivity of U2OS 
and CAL51 (human breast cancer) cells using a clonogenic 
assay, exposing cells to olaparib for 2 wk. We observed in both 
cell lines synergistic reduction of colonies in olaparib-treated, 
TOP BP1-depleted cells at levels of suppression similar to that 
caused by siBRCA2 (Fig.  1  D and Fig. S1, A–C). Analysis 
of whole cell lysates (WCLs) from TOP BP1-depleted cells 
treated with olaparib showed synergistic induction of DNA 
DSB markers: activated CHK2 kinase (pCHK2 T68) and 
RPA32 phosphorylated at serines 4/8 and threonine 21, which 
were mostly absent in TOP BP1-depleted cells or control 
cells treated with olaparib (Fig.  1  E). As expected, olaparib 
treatment induced RPA32 phosphorylation at serine 33 and the 
activatory ATR-mediated phosphorylation of CHK1 at serine 
317, the latter modification being impaired in the TOP BP1-
depleted cells because TOP BP1 is required for ATR activation. 
These results indicated that TOP BP1 silencing causes olaparib 
hypersensitivity and raised a question of potential TOP BP1 
aberrations in human tumor types most relevant to treatment 
with PARPi. Strikingly, although ovarian cancer is the only type 
of cancer so far approved for clinical treatment by olaparib, 
there has been no report on TOP BP1 protein expression in 
this tumor. Here we have performed an immunohistochemical 
analysis of 136 human ovarian carcinomas. Although most 
tumors showed normal levels of TOP BP1 comparable with a 
normal ovary, 8 and 10 carcinomas showed aberrant reduction 
and overabundance of TOP BP1 protein, respectively (Fig. S1 
D). The rather modest frequencies of TOP BP1 aberrations in 
our cohort are reminiscent of studies of breast cancer (Going 
et al., 2007; Liu et al., 2009) and likely reflect the fact that 
TOP BP1 gene mutations are more common in some other types 
of cancer (https ://www .intogen .org /search ?gene =TOP BP1).
Because the known synthetic lethal interactions with 
PARPi commonly involve HR pathway genes (Lord et al., 
2015) and we found elevated DSB markers in TOP BP1- 
depleted cells treated with olaparib (Fig. 1, C and E), we next 
examined whether olaparib sensitivity could reflect defective 
Figure 1. TOP BP1 silencing sensitizes tumor cells to PARP inhibition. (A) 
Staining of U2OS cells treated with indicated siRNAs, exposed for 3 d to 
5 µM olaparib. Bar, 10 µm. (B) Quantification of micronuclei from cells 
shown in A. (C) Quantification of γH2AX signal intensity from U2OS cells 
treated as in A. (D) Clonogenic assay of U2OS cells transfected with indi-
cated siRNAs in the presence of olaparib. (E) U2OS cells were transfected 
with indicated siRNAs and treated with 10 µM olaparib for 24 h; cell lysates 
analyzed by immunoblotting with indicated antibodies. Error bars repre-
sent SDs, n = 3. Significance determined by two-tailed t test: *, P < 0.05.
o
n
 D
ecem
ber 20, 2016
D
ow
nloaded from
 
Published January 25, 2016
ToP BP1 in homologous recombination • moudry et al. 283
HR. As a surrogate of HR activity, we quantified formation 
of RAD51 ionizing radiation (IR)–induced foci (IRIF) in 
cyclin A–positive (S/G2-phase) cells. Indeed, TOP BP1-depleted 
U2OS cells showed a pronounced reduction in this RAD51 IRIF 
assay (Fig. 2, A–C). Abrogation of RAD51 IRIF was not caused 
by reduced RAD51 protein levels (Fig. 2 D) and was statisti-
cally significant at 2, 4, 10, and 15 h after IR (Fig. 2 B). Three 
TOP BP1 siRNAs, which efficiently reduced TOP BP1 protein 
levels, recapitulated RAD51 IRIF abrogation without affecting 
RAD51 abundance (Fig. S2, A and B). Depletion of TOP BP1 
also impacted RAD51 foci formation on DSB induction by 
camptothecin (CPT; Fig. S2 C). There were no marked changes 
in cell cycle distribution on TOP BP1 depletion (Fig. S2 E), and 
a similar percentage of TOP BP1-depleted cells accumulated in 
mitosis after 4-h treatment with nocodazole (Fig. S2 F), indicat-
ing that cell cycle indirect effects were unlikely to account for our 
results. We then directly assessed HR activity in the TOP BP1- 
silenced cells using the traffic light reporter system (Certo et 
al., 2011). Consistent with Morishima et al. (2007), TOP BP1- 
depleted cells showed reduced HR activity (Fig. S2 D). To gain 
more mechanistic insight into TOP BP1’s role in RAD51 foci 
formation, we examined which TOP BP1 domains are required 
for formation of RAD51 IRIF. TOP BP1 contains nine BRCT do-
mains (Rappas et al., 2011) and an ATR-activation domain (Ku-
magai et al., 2006). First, we generated three large RNAi-resistant 
GFP-tagged TOP BP1 deletion mutants (Fig. 2 E) in which N- 
terminal, central, or C-terminal parts were deleted and expressed 
those mutants to examine their ability to rescue the impaired 
RAD51 IRIF formation in cells depleted of endogenous TOP 
BP1. Whereas TOP BP1 full-length and TOP BP1 ΔN and Δcen-
tral complemented RAD51 IRIF formation, TOP BP1 ΔC mutant 
was unable to rescue RAD51 IRIF formation (Fig. 2 F), suggest-
ing that TOP BP1 domains within the C terminus are required 
for RAD51 IRIF. Second, we generated another set of RNAi- 
resistant GFP-tagged TOP BP1 mutants, including deletions of 
AAD, BRCT7, BRCT8, and BRCT domains 7/8. Among these, 
only the TOP BP1 ΔAAD could rescue RAD51 IRIF formation 
in TOP BP1-depleted cells (Fig. 2 F). Furthermore, expression of 
the BRCT domains 7/8–containing fragment alone did not rescue 
RAD51 IRIF in TOP BP1-depleted cells (Fig. S3 A). These res-
cue experiments indicated that both C-terminal BRCT domains 
7/8 are essential, but not sufficient, for formation of RAD51 IRIF.
To further characterize the role of BRCT domains 7/8 in 
regulation of RAD51 IRIF formation, we exploited a recently 
identified small molecular compound, calcein AM (CalAM), 
that avidly binds to BRCT domains 7/8 (Chowdhury et al., 2014) 
and thereby alters their engagement in protein–protein interac-
tions, including TOP BP1 oligomerization (Liu et al., 2013). 
Indeed, 2-h pretreatment of U2OS cells with CalAM resulted 
in reduced formation of RAD51 foci, and 16-h pretreatment 
completely inhibited RAD51 IRIF (Fig. 2 G). If the TOP BP1 
function targeted by CalAM is required for RAD51 IRIF and 
therefore HR, exposure to CalAM should sensitize cells to 
PARPi. Indeed, although low doses of olaparib or CalAM used 
separately only slightly reduced numbers of colonies in a clo-
nogenic assay, combined olaparib and CalAM showed a more 
pronounced effect (Fig. 2 H). Control experiments with coex-
pressed GFP- and mCherry-tagged wild-type TOP BP1 in 293T 
cells, and biochemical analyses of endogenous TOP BP1 in 
U2OS cells by nondenaturing gel electrophoresis and Western 
blotting, showed altered TOP BP1 protein patterns on treatment 
with CalAM, but without a pronounced alteration of TOP BP1’s 
oligomerization status (unpublished data). In addition, although 
treatment with CalAM reduced the known interaction between 
BRCT domains 7/8 of endogenous TOP BP1 and the DNA re-
pair protein BACH1 (Fig. S3 D), BACH1 knockdown had only 
modest effect on RAD51 IRIF (Fig. S3, B and C). Overall, 
although these results support the essential role of BRCT do-
mains 7/8 in TOP BP1’s ability to facilitate RAD51 IRIF forma-
tion, the mechanistic basis of such function remained unclear.
In search for the underlying mechanism, we assessed the 
potential role of TOP BP1 in HR, a process that can be separated 
into several distinct phases, including DNA end resection and 
chromatin loading of RPA and RAD51, steps that can be visualized 
Figure 2. TOP BP1 regulates HR. (A) Immunofluorescence of U2OS cells 
treated with indicated siRNAs and IR (2 Gy, 2 h). Bar, 10 µm. (B) Quan-
tification of RAD51 foci in cyclin A–positive U2OS cells treated with IR (2 
Gy). Cells with more than five RAD51 foci among 200 cells were scored. 
(C) Quantification of RAD51 foci number in cyclin A–positive U2OS cells 
treated as in A.  >200 cells were scored per experiment. (D) Immuno-
blots of U2OS cell lysates 3 d after transfection with indicated siRNAs. 
(E) Scheme of TOP BP1 domains. Numbers indicate nine BRCT domains. 
(F) Quantification of RAD51 foci in cyclin A–positive U2OS cells treated 
with indicated siRNAs, complemented with indicated GFP-TOP BP1* con-
structs, irradiated (2 Gy, 2 h) and immunostained. Cells with more than 
five RAD51 foci out of 200 cells were scored. (G) Quantification of RAD51 
foci in cyclin A–positive U2OS cells treated with CalAM (4 µM) and IR (2 
Gy, 2 h). Cells with more than five RAD51 foci of 200 cells were scored. 
(H) Clonogenic assay of U2OS cells in the presence of olaparib (0.1 µM), 
CalAM (10 nM), or both drugs. Error bars represent SDs, n = 3. Signifi-
cance determined by two-tailed t test: *, P < 0.05.
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by formation of microscopically detectable foci. First, we com-
pared the extent of ssDNA by detection of BrdU incorporation 
under nondenaturing conditions (a surrogate marker for DNA 
end resection) and formation of RPA, BRCA1, and RAD51 
foci in irradiated control and TOP BP1-depleted cells. Although 
neither DNA end resection nor RPA loading showed deviation 
from control values, formation of RAD51 foci was impaired 
by TOP BP1 knockdown (Fig. 3, A and B). Using biochemical 
cell fractionation, we compared accumulation of RPA70 and 
RAD51 proteins in chromatin-enriched fractions (CHEFs) on IR. 
TOP BP1 knockdown abolished RAD51 accumulation in CHEFs, 
whereas RPA70 accumulated normally (Fig. 3 C). These results 
suggested that TOP BP1 acts at the level RAD51 chromatin 
loading. BRCA2 physically interacts with RAD51 (Chen et al., 
1998) and is essential for RAD51 loading on chromatin (Yuan 
et al., 1999; Reuter et al., 2014; Shahid et al., 2014); hence, we 
assessed BRCA2 recruitment to damage sites. Because we were 
unable to detect BRCA2 IRIF with available antibodies against 
BRCA2, we tested recruitment of endogenous BRCA2 to DNA 
damage sites induced by laser microirradiation (Bekker-Jensen 
et al., 2006). BRCA2 localized to laser stripes independently of 
TOP BP1 (Fig. 3 D), whereas RAD51 recruitment was reduced in 
TOP BP1-depleted cells (Fig. S3 E). These results indicated that 
TOP BP1 functions in HR at the level of RAD51 chromatin load-
ing, apparently without affecting BRCA2 function.
RAD51 is phosphorylated by PLK1 kinase at serine 14 in 
response to DNA damage and subsequently by CK2 at threonine 
13, thereby facilitating RAD51 recruitment to DNA damage 
sites (Yata et al., 2012). We found that CPT treatment increased 
RAD51 phosphorylation at serine 14, and TOP BP1 knockdown 
prevented this modification (Fig. 4 A). Notably, compared with 
efficient chromatin accumulation of wild-type TOP BP1, a non-
phosphorylatable mutant RAD51 protein in which serine 14 
was replaced by alanine showed impaired chromatin accumula-
tion (Fig. 4 B). Consistently, pretreatment of cells with CK2 or 
PLK1 inhibitors reduced formation of RAD51 IRIF (Fig. 4 C). 
Efficiency of PLK1 and CK2 inhibitors was tested on phos-
phorylations of S1790 of LRRK1 (Hanafusa et al., 2015) and 
S380 of PTEN (Martins et al., 2014), respectively (Fig. S3 F). 
Because RAD51 phosphorylation at serine 14 and threonine 
13 facilitates RAD51 recruitment to IR-induced damage sites 
(Yata et al., 2012), absence of RAD51 phosphorylation at serine 
14 could explain the observed abrogation of RAD51 chromatin 
loading and RAD51 IRIF formation in TOP BP1-depleted cells.
Given that TOP BP1 provides a scaffold support for var-
ious protein–protein interactions, we considered that TOP BP1 
might interact with PLK1. Indeed, reciprocal coprecipitation 
experiments with antibodies to PLK1 and TOP BP1 revealed 
interactions between endogenous PLK1 and TOP BP1 in ex-
tracts from U2OS cells (Fig. 5, A and B). Reminiscent of the 
scenario reported for the PLK1–BRCA2 interaction (Yata et 
al., 2014), the TOP BP1-PLK1 complex was more abundant in 
nocodazole-treated, mitotic cells with a high abundance of ac-
tive PLK1. Consistent with its functional significance for HR, 
the complex between endogenous TOP BP1 and PLK1 was 
abolished on pretreatment of cells with the BRCT domains 7/8– 
targeting CalAM, used at the concentration that prevented 
RAD51 IRIF formation (Figs. 5 C and 2 G).
In this study, through an unbiased siRNA screen, we iden-
tified and validated TOP BP1 protein as a novel determinant of 
PARPi sensitivity. We conclude that TOP BP1 is required for 
RAD51 loading on chromatin and formation of RAD51 IRIF, 
whereas the earliest steps of HR, DNA end resection and RPA, 
and BRCA1 and BRCA2 recruitment are TOP BP1 indepen-
dent. Furthermore, TOP BP1 C-terminal BRCT domains 7/8 are 
essential for this novel role in HR. We also show that TOP BP1 
physically interacts with PLK1 kinase. Collectively, we propose 
a model for a plausible scaffold role of TOP BP1 in promoting 
PLK1-mediated phosphorylation of RAD51 at serine 14, a pre-
requisite for efficient formation of RAD51 IRIF and activity of 
HR (Fig.  5 D). Although this novel function is important for 
HR-mediated DSB repair, it does not exclude the possibility 
that additional aspects of TOP BP1 function contribute to HR or 
other DNA repair pathways, for example in response to replica-
tion stress. Apart from contributing to our understanding of ge-
nome integrity maintenance through TOP BP1, our results may 
also inspire assessment of TOP BP1 as a candidate biomarker 
for targeted treatment of tumor subsets with PARPis.
Figure 3. TOP BP1 is dispensable for DNA end resection and RPA32 load-
ing. (A) Immunofluorescence of U2OS cells treated with indicated siRNA 
(3 d) and irradiated (2 Gy, 2 h). Cells were incubated in 10 µM BrdU for 
48 h before fixation for detection of ssDNA. (B) Quantification of BrdU, 
RPA32, and RAD51 foci from cells shown in A. Cells with more than five 
foci of 200 cells were scored. (C) Immunoblots of CHEFs and WCLs from 
U2OS cells treated with indicated siRNAs and IR (10 Gy, 2 h). Levels of 
RAD51 and RPA70 normalized to histone H3 and nonirradiated siCON ly-
sate. (D) Immunofluorescence of U2OS cells treated with indicated siRNAs, 
grown for 3 d, and microirradiated. Arrowheads indicate laser microirra-
diated regions. Bars, 10 µm. Error bars represent SDs, n = 3. Significance 
determined by two-tailed t test: *, P < 0.05.
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Materials and methods
Cell lines
Human U2OS, CAL51, 293T, and HeLa cell lines were grown in 
DMEM with 10% FBS and penicillin/streptomycin (Sigma-Aldrich). 
To generate stable isogenic U2OS cell lines with inducible expression 
of FLAG-Rad51 variants, Flp-In T-REx U2OS cells were cotransfected 
with pOG44 and pcDNA5/FRT/TO/FLAG-Rad51 vectors (Yata et al., 
2012) and stable clones were selected with hygromycin.
Chemicals
Olaparib was provided by Astra Zeneca. PLK1 inhibitor volasertib and 
CK2 inhibitor silmitaserib were purchased from Selleckchem. CalAM 
was purchased from Sigma-Aldrich.
RNAi
All siRNA transfections were performed using Lipofectamine RNAi-
MAX (Invitrogen) according to the manufacturer’s instructions. All 
siRNA duplexes were purchased from Ambion: siCON (negative control 
#1, AM4635, 5′-AGU ACUGC UUACG AUACG GTT-3′), siTOP BP1#1 
(s21823, 5′-GGA UAUAU CUUUG CGGUU UTT-3′), siTOP BP1#2 
(s21824, 5′-GCA GAACU GUUGC GGAUU ATT-3′), siTOP BP1#3 
(s21825, 5′-GCU CUGUA AUAGU CGACU ATT-3′), siBRCA2 (s2085, 
5′-GGA UUAUA CAUAU UUCGC ATT-3′), siBACH1#1 (s38386, 5′-
GAA UAACC CAAGU CGCUA UTT-3′), and siBACH1#2 (s38385, 5′-
GAC UAUCU UUUUA GGCAA ATT-3′).
Plasmids
Plasmid transfections were performed using FuGENE 6 (Roche) 
according to the manufacturer’s instructions. To generate siRNA- 
insensitive GFP-TOP BP1* mutants, silent mutations were introduced 
into the siTOP BP1#3 target sequence in the TOP BP1 coding region 
of the pEGFP-C1-hTOP BP1 plasmid using the QuikChange II Site- 
Directed Mutagenesis kit (Stratagene).
The construct pSNV2-GFPB-YTA-NLS-hTOP BP1-1258-1522 
for GFP-BRCT7/8 expression was provided by T. Halazonetis (Univer-
sity of Geneva, Geneva, Switzerland; Cescutti et al., 2010).
Figure 4. TOP BP1 is required for phosphorylation of RAD51 at Ser14. 
(A) Immunoblots of RAD51 immunoprecipitates (IPs) and WCLs from U2OS 
cells treated with indicated siRNAs and CPT (1 µM, 2 h). (B) Immunoblots 
of WCLs and CHEFs from U2OS cells expressing Flag-RAD51 variants 
treated with indicated siRNAs and IRs (10 Gy, 2  h). (C) Quantification 
of RAD51 foci in cyclin A–positive U2OS cells treated with inhibitors of 
CK2 (10 µM) or PLK1 (1 µM) for 16 h and IRs (2 Gy, 2 h). Cells with more 
than five RAD51 foci of 200 cells were scored. Error bars represent SDs, 
n = 3. Significance determined by two-tailed t test: *, P < 0.002. Figure 5. TOP BP1 interacts with PLK1. Immunoblots of control, anti-PLK1 
(A) or anti-TOP BP1 (B) immunoprecipitates (IPs) from U2OS cells treated 
or not with nocodazole (40 ng/ml) for 4  h before collection. (C) Im-
munoblots of control and anti-PLK1 IPs from U2OS cells treated or not 
with CalAM (4 µM) or nocodazole (40 ng/ml) for 4 h before collection. 
(D) Model of TOP BP1 role in HR.
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The construct for expression of GFP-TOP BP1 ΔN (deleted aa 
1–519) was generated by double digestion of pEGFP-C1-hTopBP1 with 
restriction enzymes ApaI and Bpu1102I followed by blunting by mung 
bean nuclease (New England Biolabs) and ligation of the blunted ends.
The construct for expression of GFP-TOP BP1 Δcentral (de-
leted aa 526–1,000) was generated by double digestion of pEGFP- 
C1-hTopBP1 with restriction enzymes Bpu1102I and Eco32I followed 
by ligation with annealed oligos RTP41 (5′-TGA GCCCT TGAAT 
GATTC TACT-3′) and RTP42 (5′-AGT AGAAT CATTC AAGGGC-3′).
The construct for expression of GFP-TOP BP1 ΔC (deleted 
aa 1,001–1,522) was generated by double digestion of pEGFP-C1-
hTopBP1 with restriction enzymes Eco32I and BamHI followed by 
blunting by mung bean nuclease treatment and ligation of the blunted 
ends. NLS was added to this construct by site-directed mutagenesis.
Small internal deletion mutants of GFP-TOP BP1, includ-
ing ΔAAD (deleted aa 993–1,196), ΔBR CT7 (1,259–1,351), 
ΔBR CT8 (1,389–1,486), and ΔBR CT7/8 (1,259–1,486), were gen-
erated by site-directed mutagenesis. All prepared constructs were 
verified by sequencing.
Antibodies
We used the following rabbit antibodies: TOP BP1 (ab2402; Abcam), 
RAD51 (sc8349; Santa Cruz; ab63801; Abcam), pRAD51 S14 (Yata 
et al., 2012), cyclin A (NCL-CYC LINA; Leica), RPA70 (ab79398; 
Abcam), pRPA32 T21 (ab61065; Abcam), pRPA32 S4/8 (A300-245A; 
Bethyl), pRPA32 S33 (NB100-544; Novus), pCHK1 S317 (2344; Cell 
Signaling), pCHK2 T68 (2661; Cell Signaling), H3 (ab1791; Abcam), 
pH3 S10 (06–570; Millipore), BACH1 (sc-28738; Santa Cruz), pPTEN 
S380 (9551; Cell Signaling), pLRRK1 S1790 (H. Hanafusa, Nagoya 
University, Nagoya, Japan; Hanafusa et al., 2015); mouse antibodies: 
γH2AX (05–636; Millipore), cyclin A (sc-751; Santa Cruz), BrdU 
(RPN20AB; AP Biotech), RPA32 (ab2175; Abcam), BRCA1 (sc-
6954; Santa Cruz), BRCA2 (OP95; Millipore), CHK1 (sc-8408; Santa 
Cruz), Importin-β (ab2811; Abcam), Lamin A/C (sc-7292; Santa Cruz), 
α-tubulin (sc-8035; Santa Cruz), PLK1 (05–844; Millipore; 331700; 
Zymed); and goat antibody: γ-tubulin (sc-7396; Santa Cruz).
Clonogenic survival assay
Cells were transfected with siRNAs; 24 h later, they were seeded to 
6-cm-diameter dishes; and after the next 24 h, they were treated with 
olaparib or vehicle. Colonies were grown for 10 d, fixed in 70% etha-
nol, and stained with 1% crystal violet in ethanol. Colonies of >50 cells 
were counted, and the surviving fractions were calculated.
Immunofluorescence
Cells cultured on glass coverslips were fixed in 4% formaldehyde for 15 
min at RT, permeabilized for 5 min with 0.2% (vol/vol) Triton X-100 in 
PBS, washed in PBS, and incubated with primary antibodies for 60 min 
at RT. After the washing step, the coverslips were incubated with goat 
anti–rabbit or goat anti–mouse Alexa Fluor 488, 568, or 647 secondary 
antibodies (Invitrogen) for 60 min at RT, washed with PBS, and mounted 
using Vectashield mounting reagent with DAPI (Vector Laboratories). 
ssDNA was detected by BrdU antibody under nondenaturing conditions 
after 48-h incubation of cells in culture medium supplemented with 
5 µM BrdU. For the RAD51 IRIF assay, sc8349 Ab (Santa Cruz) was 
used initially, and after the next batch failed completely, it was replaced 
by ab63801 (Abcam), accounting for different starting basal values of 
RAD51 in Figs. 2 B and 3 B versus Figs. 2 (F and G) and 4 C.
Microscope image acquisition
Microscope images were acquired using a confocal microscope 
(LSM510; Carl Zeiss) mounted on inverted microscope (Axiovert 
100M; Carl Zeiss) equipped with a Plan-Apochromat 63×/1.4 oil im-
mersion objective (Carl Zeiss) at RT. Image acquisition and analysis 
was performed using LSM ZEN software (Carl Zeiss). Dual-color 
confocal images were acquired using laser lines 488 and 543 nm 
for excitation of Alexa Fluor 488 and 568 dyes (Invitrogen), respec-
tively. Automated multichannel image acquisition was performed 
using high-content screening station scan^R (Olympus) equipped 
with motorized microscope (IX81; Olympus), UPlanSApo 40×/0.95 
air immersion objective (Olympus), and digital monochrome elec-
tron multiplying charge coupled device camera (C9100; Hamamatsu). 
Image acquisition and analysis was performed using scan^R acquisi-
tion and analysis software (Olympus).
Laser microirradiation
Cells grown on glass coverslips were presensitized with 10  µM 
Hoechst 34580 (Life Technologies) for 5 min. For microirradia-
tion, the cells were placed in a LabTek chamber and mounted on the 
stage of a custom-designed PALM MicroBeam with a 335-nm UV-A 
pulsed laser (Carl Zeiss).
Immunohistochemical analysis
The cohort (n = 136) of formalin-fixed, paraffin-embedded human 
ovarian carcinomas (Department of Pathology, University Hospital 
in Las Palmas) included the following histopathological subtypes of 
tumors: serous (n = 61), mucinous (n = 17), clear-cell (n = 22), en-
dometrioid (n = 22), mixed type (n = 5), and undifferentiated (n = 9). 
For a sensitive immunohistochemistry procedure without nuclear coun-
terstaining, the slides were deparaffinized, subject to antigen retrieval 
(15 min heating with the Target retrieval solution, pH 9, code S2367; 
Dako), and incubated with the primary rabbit antibody against human 
TOP BP1 (ab2402; diluted 1:4,000; Abcam) overnight, followed by the 
indirect streptavidin–biotin–peroxidase method using the Vectastain 
Elite kit (Vector Laboratories) and nickel sulfate-based chromogen en-
hancement detection. Normal rabbit serum served as a negative control. 
Staining patterns were evaluated by an experienced oncopathologist; 
TOP BP1 protein abundance was compared with sections of normal 
ovary and surrounding normal (stromal) cells within each tumor sec-
tion (as an internal control) and was categorized as normal, aberrantly 
reduced, or overexpressed.
Immunoblotting
WCLs were prepared in Laemmli sample buffer (LSB; 50 mM Tris, 
pH 6.8, 100  mM DTT, 2% SDS, 0.1% bromophenol blue, and 10% 
glycerol), separated by SDS-PAGE, and transferred to nitrocellulose 
membranes (GE Healthcare). The membranes were blocked with 5% 
(wt/vol) dry milk in 0.1% (vol/vol) Tween-20 in PBS and probed with 
the primary antibodies, followed by HRP-labeled secondary antibodies 
(Vector Laboratories and Santa Cruz), and visualized using ECL detec-
tion reagents (GE Healthcare).
Cellular fractionation
Cells were washed three times by PBS, and soluble proteins were re-
moved by incubation of cells with 0.5% Triton X-100 in PBS for 5 min 
on ice. The remaining pellet was washed by 0.5% Triton X-100 in PBS 
and resuspended in 2× LSB.
Immunoprecipitation
To prepare lysates for immunoprecipitation, cells were washed three 
times in PBS and lysed in TNE buffer (150 mM NaCl, 50 mM Tris-HCl, 
pH 8.0, 1 mM EDTA, 0.5% NP-40) supplemented with cOmplete and 
PhosSTOP tablets (Roche). After 30 min incubation on ice, lysates were 
cleared by centrifugation. Where appropriate, antibodies were added to 
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lysate and incubated for 16 h at 4°C. Lysates were then incubated with 
25  µl of either Dynabeads Protein G (Novex) or Dynabeads M-280 
Sheep anti Rabbit IgG (Novex) for 1 h at 4°C. Ig–antigen complexes 
were washed extensively before elution in 2× LSB before SDS-PAGE.
Flow cytometry
Cells were harvested by trypsinization, fixed in 70% ethanol, and re-
suspended in propidium iodide buffer Facsflow (BD). Samples were 
incubated for 30 min at 37°C before analysis. Cell cycle analysis was 
performed using flow cytometer FAC SCalibur (BD). Mitotic entry was 
examined by staining with primary antibody for pH3 S10 followed by 
FITC-conjugated secondary antibody.
Online supplemental material
Fig. S1 shows sensitivity of TOP BP1-depleted CAL51 cells to olaparib 
and efficiency of siRNA-mediated knockdowns. Fig. S2 shows effects 
of multiple TOP BP1 siRNAs on RAD51 foci formation and documents 
effects of TOP BP1 knockdown on cell cycle. Fig. S3 shows RAD51 
IRIF after complementation of TOP BP1-depleted cells with the BRCT 
domains 7/8 construct, effect of BACH1 knockdown on RAD51 IRIF, 
impact of CalAM on TOP BP1-BACH1 interaction, and impaired 
accumulation of RAD51 on microirradiated regions in TOP BP1-
depleted cells. Online supplemental material is available at http ://www 
.jcb .org /cgi /content /full /jcb .201507042 /DC1.
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